

Decade in review: a new era for RET-rearranged lung cancers

Noura J. Choudhury¹, Alexander Drilon^{1,2}

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Weill Cornell Medical College, New York, NY, USA

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Alexander Drilon, MD. Memorial Sloan Kettering Cancer Center, 545 E73rd St, 22nd FL, New York, NY 10021, USA.

Email: drilona@mskcc.org.

Abstract: Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including *ALK* and *ROS1* kinase fusions. *RET* fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first identified more than thirty years ago, targeted therapy for *RET* fusion-positive lung cancers was only explored in the last decade. Whereas repurposed multikinase inhibitors were initially tested, selective inhibitors *RET* inhibitors have dramatically improved outcomes for patients whose tumors harbor these alterations. In 2020, the US Food and Drug Administration approved selpercatinib, a selective *RET* inhibitor, for adults with lung and thyroid cancers with *RET* rearrangements or mutations, making it the first targeted therapy to be approved for *RET*-altered cancers. While resistance to selective *RET* inhibition has been described, next-generation *RET* inhibitors are already being explored for patients who progress on prior *RET* kinase inhibitors.

Keywords: *RET*-fusion; non-small cell lung cancer; targeted therapies; multikinase inhibitors; LOXO-292; BLU-667

Submitted Feb 29, 2020. Accepted for publication May 26, 2020.

doi: 10.21037/tlcr-20-346

View this article at: <http://dx.doi.org/10.21037/tlcr-20-346>

Introduction

RET alterations are estimated to occur in approximately 2% of all human cancers (1). The oncogenic potential of *RET* was first identified in 1985 after the discovery that transfection with human lymphoma DNA could transform NIH 3T3 fibroblasts (2). *RET* fusions were later identified in papillary thyroid cancer in the 1980s, followed by the discovery of germline *RET* mutations as the causative genetic link in multiple endocrine neoplasia type 2 (*MEN2*) syndromes. In all, *RET* alterations are found in 5–10% of papillary thyroid cases (3) and the majority of medullary thyroid cancer (*MTC*) cases (4).

The *RET* proto-oncogene on chromosome 10q11.2 encodes for a transmembrane glycoprotein receptor tyrosine kinase whose ligands belong to the glial-derived neurotrophic factor (*GDNF*) family. In normal cellular functioning, *RET* signaling is essential for the development

and maintenance of the kidneys (5) and enteric nervous system (6). Loss-of-function *RET* mutations can result in hereditary Hirschsprung disease (7) and some forms of congenital malformations of the kidneys and urinary tract (8). *RET* activation occurs when its *GDNF* ligands bind to cell membrane-bound *GDNF* family receptor (*GFR*) co-receptors, which induces *RET* homodimerization and autophosphorylation within the *RET* intracellular tyrosine kinase domains (9). This activates downstream signaling pathways involved in normal cellular differentiation and proliferation, such as the *RAS*, *MAPK*, *PI3K* and *JAK-STAT* pathways (10-12).

In non-small cell lung cancer (*NSCLC*), oncogenic activation of *RET* occurs by chromosomal rearrangement, which fuses the 3' coding region for the *RET* kinase domain on chromosome 10 with a 5' upstream partner gene containing one of several possible domains, such as a coiled-coil or *LIS1* homology (13-15). This fusion induces ligand-




Figure 1 Timeline of advances in *RET*-rearranged NSCLC. Since its first identification in NSCLC in 2012, *RET* rearrangements have been investigated as a potential target in multiple phase II trials of targeted therapies in the last decade. NSCLC, non-small cell lung cancer.

independent dimerization, constitutive *RET* activation, and oncogenesis. Intrachromosomal rearrangements are most frequently seen, with partner genes such as *KIF5B*, *CCDC6*, and *NCOA4* also originating from chromosome 10, although interchromosomal partners have also been identified (16). The specific fusion partner and breakpoints locations in *RET* or upstream partners impact the properties of the formed oncoprotein, such as its subcellular location. Fusion partners also confer distinctive properties such as higher levels of activated *RET* oncoprotein (13) and formation of multikinase signaling hubs (17), both of which are seen with *KIF5B-RET* and are postulated to impact the fusion protein's drug sensitivity.

In contrast, in other cancer types, namely thyroid cancer but also breast and colorectal cancer (1), the primary mechanism of aberrant *RET* activation is point mutation. Mutations in the cysteine-rich extracellular domain, for example, define the hereditary syndrome MEN2A. MEN2A is characterized by the development of MTC and pheochromocytomas in the majority of patients, as well as hyperparathyroidism in a select subset (18). The hereditary syndrome MEN2B, which results in pheochromocytomas and MTC as well as a characteristic marfanoid habitus, is defined by point mutations in the intracellular kinase domain, with the most common alteration being *RET*^{M918T} (19).

RET fusions were not identified in NSCLC until 2012 (Figure 1), when four independent groups from the United States, Japan, and Korea reported *RET* fusions in 1–2% of lung cancer cases examined (13–15,20). Patients with

RET fusions tend to be young, never smokers, and more frequently had adenocarcinomas over other histological types (21), characteristics that have since been further validated (22). Of note, these fusions are also seen, although less frequently, in older patients, those with a substantial smoking history, and non-adenocarcinoma histologies. Molecular profiling should thus be unbiased in relation to clinical or pathologic features. Soon after its identification in NSCLC, *RET* became a target for molecularly-targeted therapies, the first of which were existing multikinase inhibitors (MKIs).

Multikinase inhibitors

Until recently, there were no approved therapies specifically for *RET* fusion-positive NSCLCs. Several MKIs have been shown to have modest clinical activity against *RET* fusions in phase II clinical trials, leading to their use being supported by National Comprehensive Center Network guidelines as category 2A recommendations (23). As their name implies, MKIs target *RET* as well as kinases including VEGFR2, MET, KIT, BRAF or EGFR (24), depending on the particular agent in question; this contributes both to their off-target effects and decreased effectiveness against *RET* due to pharmacokinetic limitations.

Cabozantinib was the first MKI studied in *RET*-rearranged lung cancer in a prospective clinical trial. The clinical response of the first three patients in this single-arm phase II trial were reported in 2013 (25), with the

Table 1 Prospective clinical trials of multikinase inhibitors (MKIs) in *RET*-rearranged non-small cell lung cancer

Drug	First author & year	Clinical trial phase/number of patients	ORR	Median PFS (mo)	Median OS (mo)
Cabozantinib	Drilon, 2016	II, n=26 (25 evaluable)	7/25 (28%)	5.5	9.9
	Nokikhara, 2019	I, n=2 <i>RET</i> patients	1/2 (50%)	NE	NE
Sorafenib	Horiike, 2016	II, n=3	0/3 (0%)	NE	NE
Vandetanib	Lee, 2017	II, n=17	3/17 (18%)	4.5	11.6
	Yoh, 2017	II, n=19	9/19 (47%)	4.7	11.1
Lenvatinib	Hida, 2019	II, n=25	4/25 (16%)	7.3	NE
RXDX-105	Drilon, 2019	I, n=31	6/31(19%)	NE	NE

The clinical activity of several MKIs has been tested in small prospective clinical trials. ORR, objective response rate; mo, months; PFS, progression-free survival; OS, overall survival; NE, not evaluable or not reached in published report. RXDX-105 has since been discontinued by the manufacturer.

full results of 26 patients published in 2016 (26). Enrolled patients had metastatic or unresectable NSCLC with a *RET* fusion, 20 of whom had received at least one prior line of chemotherapy. Of the 25 patients analyzed, seven (28%) demonstrated a partial response (PR) with an additional nine (36%) achieving stable disease (SD). There were no complete responses (CR). The median progression-free survival (PFS) was 5.5 months with an overall survival (OS) of 9.9 months.

Vandetanib, lenvatinib, sorafenib and RXDX-105 have also been studied in prospective clinical trials (*Table 1*). Of these, a Japanese trial of 18 patients treated with vandetanib reported the highest objective response rate (ORR) of 53% (27), with a median PFS of 6.5 months and an OS of 13.5 months (28). Other phase II trials of sorafenib (3 patients), lenvatinib (25 patients), and vandetanib (19 patients) reported ORRs ranging from 0 to 18% and median PFS ranging from 4.7 to 7.3 months (29-32). Of note, of the MKIs, RXDX-105 is the only one that relatively spares VEGFR2, a characteristic which was hypothesized to allow tolerable dose up-titration to more clinically active plasma concentration levels. In a phase I/II trial, however, the ORR was similar to those reported for other MKIs (ORR =19% or 6/31 patients) (33). RXDX-105 was discontinued later in 2019.

Retrospective series of MKIs have reported similar response rates. The GLORY database included 169 patients with *RET*-rearranged NSCLC, with 53 patients receiving at least one MKI (22). Cabozantinib, which 21 patients received, had the highest ORR of 37%, followed by vandetanib (18%) and sunitinib (22%). Responses were also seen with lenvatinib and nintedanib. No responses were seen with sorafenib, alectinib, ponatinib and regorafenib,

although the number of patients who received each agent were in the single digits. The median OS for patients in the registry was 6.8 months, which highlighted the need for a more active *RET* inhibitor beyond standard MKIs. The results of the interventions in GLORY, as well as three other retrospective series of alectinib (34,35) and vandetanib (36), are summarized in *Table 2*.

MKI limitations

The response to MKIs in *RET*-rearranged NSCLC was notably disappointing compared to other targeted therapies in lung cancer. For context, the ORRs for osimertinib, alectinib, and entrectinib for untreated *EGFR*, *ALK*, and *ROS1*-altered NSCLC are 80% (37), 83% (38), and 77% (39), respectively. The relatively modest response and limited overall durability for MKIs in *RET*-fusion positive NSCLCs is likely due to several factors, the most important of which are non-selectivity for *RET*, potent inhibition of non-*RET* targets such as VEGFR2 (which contributes to dose-limiting toxicity and drug discontinuation), and intrinsic and acquired resistance.

Off-target kinase inhibition by MKIs contributes to the comparative lack of efficacy in *RET*-rearranged disease by several mechanisms. First, the concurrent inhibition of non-*RET* targets mediates some of the most significant toxicities seen with MKIs. VEGFR2 inhibition can cause hypertension, hand-foot syndrome, and proteinuria (40), while *EGFR* inhibition can contribute to acneiform rash and diarrhea (41). Cabozantinib, vandetanib and lenvatinib all more potently inhibit VEGFR2 than *RET* (42,43). These treatment-related toxicities lead to dose reductions

Table 2 Retrospective studies of multikinase inhibitors (MKIs) in *RET*-rearranged non-small cell lung cancer (NSCLC)

Drug	First author & year	Number of patients	ORR	Median PFS (mo)	Median OS (mo)
Cabozantinib	Gautschi, 2017	19	7/19 (37%)	3.6	4.9
Vandetanib	Gautschi, 2017	11	2/11 (18%)	2.9	10.2
	Platt, 2015	3	0/3 (0%)	NE	NE
Lenvatinib	Gautschi, 2017	2	1/2 (50%)	NE	NE
Sorafenib	Gautschi, 2017	2	0/2 (0%)	NE	NE
Sunitinib	Gautschi, 2017	9	2/9 (22%)	2.2	6.8
Alectinib	Lin, 2016	4	1/4 (25%)	NE	NE
	Gautschi, 2017	2	0/2 (0%)	NE	NE
	Ribeiro, 2020	4	0/4 (0%)	NE	NE
Ponatinib	Gautschi, 2017	2	0/2 (0%)	NE	NE
Regorafenib	Gautschi, 2017	1	0/1 (50%)	NE	NE
Nintedanib	Gautschi, 2017	2	1/2 (50%)	NE	NE

The majority of these results come from the GLORY international registrational database of *RET*-rearranged NSCLC. ORR, objective response rate; mo, months; PFS, progression-free survival; OS, overall survival; NE, not evaluable.

Table 3 Tolerability of RET inhibitors

Drug	Dose-reduction rate	Drug-discontinuation rate
Cabozantinib	19/26 (73%)	2/26 (8%)
Vandetanib	4/17 (23%)	NA
	10/19 (53%)	4/19 (21%)
Lenvatinib	16/25 (64%)	5/25 (20%)
Sorafenib	1/3 (33%)	NA
Selpercatinib	NA	9/531 (1.7%)
Pralsetinib	NA	8/120 (7%)

Multikinase inhibitors (MKIs) used against *RET*-rearranged NSCLC are limited by off-target toxicity, most notably VEGFR2 kinase inhibition. The above table highlights the dose-reduction rates and the drug-discontinuation rates of several MKIs compared to the RET-selective inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667). NA, not applicable or not provided in the original studies.

and consequently, potentially decreased on-target inhibition of RET (26). Drug reduction rates for MKIs range from 23% to 73%, and are summarized in *Table 3*. Second, the lack of selectivity for RET makes it difficult for these agents to more meaningfully inhibit RET in patients due to relatively reduced potency *in vivo* and limited plasma exposures. While the latter issue is not a universal problem

among MKIs in driver-positive lung cancers (e.g., crizotinib is active against ALK/ROS1 fusions), this has been a substantial limitation for drugging RET fusions.

MKI resistance

There are known mechanisms of both intrinsic and acquired resistance with MKI therapy that may contribute to limited therapeutic response. Several acquired resistance mutations have been identified, although some have only been discovered in cell lines during *in vitro* treatment with MKIs and are hypothesized, but not proven, to propagate resistance in humans during treatment. These include *RET*^{T788N} (44), solvent-front mutation *RET*^{G810A} (45), and gatekeeper mutation *RET*^{V780L} (45,46). In contrast, both gatekeeper mutation *RET*^{V780M} (47) and *RET*^{S904F} (48), a mutation in the activation loop of the RET kinase domain, were discovered in patient samples (plasma and tissue, respectively) after progression on vandetanib. An alternative mechanism of resistance to RET inhibition derived from preclinical models includes activation of the mitogen-activated protein kinase (MAPK) pathway (44), possibly by acquisition of *NRAS* mutations (49). Finally, certain fusion partners are thought to potentially mediate intrinsic resistance to certain MKIs (50). For example, both RXDX-105 and vandetanib have diminished activity against tumors

with *KIF5B-RET* fusions (27,33), suggesting that this particular fusion may be less susceptible to non-selective RET inhibition.

Combination strategies have been utilized in attempts to overcome innate or acquired resistance postulated with MKI monotherapy. The strategy of combining vandetanib with the mammalian target of rapamycin (mTOR) inhibitor everolimus was tested in the clinic after preclinical data suggested that mTOR inhibition may both improve blood-brain barrier penetration and overcome resistance mediated by AKT amplification (51). Of 13 *RET*-rearranged patients, 7 had a PR (ORR =54%), including all three patients with brain metastases (52). However, 17/19 patients (89%) required dose reduction after the first cycle due to toxicity, indicating that tolerability may limit combination strategies.

Chemotherapy

In the GLORY registry, 84 patients with advanced disease received platinum-based chemotherapy as first-line treatment. Complete or partial responses were seen in 33 of 65 evaluable patients (51%), with a median PFS of 7.8 months and median OS of 24.8 months in 70 patients with survival data (22). A retrospective series of 18 patients with lung adenocarcinoma also demonstrated an ORR of 45% with median PFS of 19 months in patients treated with pemetrexed-based regimens, which was similar to contemporaneous responses to pemetrexed-based therapy in *ROS1*- and *ALK*-rearranged lung cancers (53). Anecdotal success of long-term (>2 years) treatment with single-agent pemetrexed has also been reported (54). In summary, chemotherapy represents a viable treatment option for patients with *RET*-rearranged NSCLC during their treatment course, and pemetrexed-based chemotherapy should be considered when possible.

Immunotherapy

Responses to immunotherapy in *RET*-rearranged lung cancer have not been characterized prospectively but are thought to be poor, based on available data from retrospective studies. The IMMUNOTARGET registry included 16 patients with *RET* fusions who were treated with immune checkpoint blockade as a second or higher line of therapy. A 6% response rate to immune checkpoint blockade was observed, with a median PFS of 2.1 months (55). Similar immunotherapy response rates

were observed for patients with *ALK* and *ROS1* driver alterations. A second retrospective series from Memorial Sloan Kettering (MSK) described a 0% response rate among 16 patients with *RET*-rearranged NSCLC treated with immunotherapy, even among patients with PD-L1 expression $\geq 1\%$, including one with PD-L1 expression $>50\%$ (56). Notably, the majority of evaluated cases in the MSK series (21/26 or 80.7%) had $<50\%$ PD-L1 expression, indicating *RET*-rearranged tumors may be less immunologically active. In contrast, a separate retrospective series included 9 *RET*-rearranged NSCLC patients treated with single-agent immunotherapy in the second or third-line setting. Of 8 evaluable patients, 3 (37%) achieved a PR, 2 (25%) achieved SD, and 3 (37%) had PD (57). Data in large, prospective cohorts is thus necessary to draw more definitive conclusions on the activity of single-agent immunotherapy. Notably, outcomes with combination chemotherapy and immunotherapy have not been described to date and represent a highly relevant data set to examine.

Selective RET inhibitors

The modest activity of MKIs against *RET* both demonstrated a clear need for more selective therapies and highlighted the ideal characteristics needed for such agents to be effective. Selpercatinib, formerly known as LOXO-292, and pralsetinib, formerly known as BLU-667, are two such agents whose early clinical results were reported in 2017–2018 and subsequently updated in 2019. Both are notable for potent *in vitro* and *in vivo* selective activity against both wild-type and mutated *RET* with significantly diminished affinity for VEGFR2 and other kinases, a crucial feature for resolving dose-limiting toxicity. From early clinical results, both agents were granted Breakthrough Therapy designation by the US Federal Drug Administration (FDA) for advanced NSCLC with *RET* fusions after progression on platinum chemotherapy, in September 2018 for selpercatinib and May 2019 for pralsetinib. In May 2020, selpercatinib was approved by the FDA for adults with advanced lung and thyroid cancers with *RET* fusions or mutations, making it the first targeted therapy approved for *RET*-driven cancers.

Selpercatinib is a highly selective, ATP-competitive small molecular *RET* inhibitor with preliminary in-human results reported in 2017. In preclinical models, selpercatinib demonstrated both >100 -fold higher potency against *RET* compared to non-*RET* kinase targets and uniform

activity in *RET*-altered xenograft models, independent of kinase fusion partner (58). In particular, the compound demonstrated promising *in vivo* activity against *RET*^{V804M}, a known acquired resistance mutation against which MKIs are postulated to be ineffective (59).

The results of LIBRETTO-001, the phase 1/2 dose escalation/expansion trial of selpercatinib in advanced solid tumors with *RET*-fusion positive alteration, were first reported at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in 2018. In 2019 at the World Conference of Lung Cancer (WCLC), the results of the first 105 patients with NSCLC who had received prior platinum chemotherapy were updated. In contrast to MKIs, the overall ORR was 68%, with 66% achieving PR and only 2% of patients demonstrating PD as their best response (60). The responses did not vary by prior treatment received (chemotherapy, immune checkpoint blockade or MKIs) or by fusion partner. Recognizing that follow up was yet to mature, the median PFS was 18.4 months, with a median 7.5 months of follow-up. The majority of treatment-related toxicities were grades 1 or 2, and included fatigue, diarrhea, constipation, dry mouth, nausea, and dyspnea, highlighting the tolerability of the compound when off-target inhibition is minimized. There were two treatment-related AEs that were grade 3 or higher, which were tumor lysis syndrome and increased ALT.

Preclinical and early clinical results of pralsetinib were published in 2018, and similarly highlighted the drug's selectivity against *RET*. In enzymatic assays, pralsetinib inhibited wild-type and mutated *RET* with sub-nanomolar potency and was 90-fold more selective for *RET* than VEGFR2 (61). The first results of the global ARROW study, a registrational trial that included both a dose escalation and dose expansion phase in multiple solid tumors, were released at ASCO in 2019. Of 57 evaluable patients, the ORR was 56%, all of which were PRs. Six patients remained on treatment for more than six months (62). The ORR for patients previously treated with chemotherapy was also high at 60% (18/30) and comparable to the results of selpercatinib. The responses seen were independent of prior therapy received and *RET* fusion partner. Pralsetinib was similarly well-tolerated, with the majority of treatment-related toxicities being grade 1 and reversible, which included constipation, neutropenia, AST elevation, hypertension, diarrhea, and dry mouth. 28% of patients had grade 2 or higher treatment-related toxicity events.

Intracranial disease

In addition to the comparatively higher response rates and tolerability of both *RET*-selective compounds, the improvement in intracranial response is particularly noteworthy. About 45% of patients with *RET* alterations in NSCLC develop brain metastases during the lifetime of treatment, demonstrating a crucial need for therapies with adequate CNS penetration (63). The CNS response rate with MKIs has been poor. In a retrospective series of 11 patients with CNS metastases treated with MKIs, only two had an intracranial response (63). In contrast, of the 11 patients with CNS metastases in LIBRETTO-001, two (18%) achieved intracranial CR, eight (73%) PR, and one SD (9%). In addition, a case report from MSK in 2019 described complete resolution of leptomeningeal disease with initiation of selpercatinib, in addition to partial response of CNS parenchymal lesions (64). Similarly, in the ARROW study, seven of nine patients with measurable brain metastases achieved shrinkage of CNS disease and no patients developed new brain metastases while on treatment.

Selective inhibitor resistance

As expected, acquired resistance eventually emerges even with highly selective *RET* inhibitors. A case series published in January 2020 described *RET*^{G810R/S/C} mutations in the *RET* solvent front detected in circulating tumor DNA in two patients just prior to progression on selpercatinib (65). The authors used structural modeling to elucidate that the mutations sterically hinder binding of selpercatinib, thus resulting in loss of activity. A possible solution to resistance mediated by *RET* solvent-front mutations is already in the clinic. TPX-0046 is a novel *RET*/*SRC* inhibitor that in enzymatic assays demonstrated high potency against *RET*^{G810R}, with a mean IC₅₀ of 17 nM, compared to IC₅₀ >500 nM with pralsetinib or selpercatinib (16). Therefore, TPX-0046 may be able to overcome solvent-front mutation-mediated resistance after treatment with selpercatinib or pralsetinib. A phase I clinical trial testing TPX-0046 in multiple solid tumors, including NSCLC, has recently opened (NCT04161391).

Future directions and conclusions

From the initial identification of *RET* rearrangements

in NSCLC in 2012 to the present, investigation into therapeutic options has rapidly grown. While treatment with repurposed MKIs held modest promise initially, the substantial increase in activity and favorable safety profile of the RET-selective agents selpercatinib and pralsetinib have made MKIs significantly less desirable first-line RET TKI options. The future of first-line RET TKI therapy for NSCLC with *RET* fusions clearly lies in selective RET inhibition, which seems to have overcome the major deficiencies seen with MKIs.

In early 2020, a randomized phase III trial of selpercatinib compared to platinum-pemetrexed with or without pembrolizumab in treatment-naïve *RET* fusion positive NSCLC is expected to open (NCT04194944). In addition, a phase III open-label trial of pralsetinib in first-line treatment of *RET* fusion positive NSCLC compared to platinum chemotherapy-based regimen is also planned for early 2020 (NCT04222972). With these trials, in addition to expanded recruitment of the existing phase II trials for both drugs, it is likely that not only one, but two drugs will likely soon be approved in a variety of regulatory environments for use in NSCLC with *RET* alterations. The beginning of the new decade, therefore, is likely the beginning of an unprecedented era for patients whose cancers harbor *RET* alterations.

Acknowledgments

Funding: The authors would like to thank the MSK Craig Thompson Cancer Center Support Grant (P30 CA008748).

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Silvia Novello, Francesco Passiglia) for the series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” published in *Translational Lung Cancer Research*. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tlcr-20-346>). The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the editorial office without any funding or sponsorship. AD reports PERSONAL FEES from Ignyta/Genentech/

Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millennium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Axis, Peerview Institute, OncLive, Paradigm Medical Communications, LLC, Remedica Ltd., ArcherDX, Foundation Medicine, PeerVoice, Research to Practice, Medscape, and WebMD, outside the submitted work; ASSOCIATED RESEARCH PAID TO THE FOLLOWING INSTITUTIONS: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar; RESEARCH collaboration with Foundation Medicine; ROYALTIES to Wolters Kluwer; OTHER relationships with Merck - Food/Beverage, Puma - Food/Beverage, Merus and Boehringer Ingelheim; CME HONORARIA from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology and Research to Practice. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Kato S, Subbiah V, Marchlik E, et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. *Clin Cancer Res* 2017;23:1988-97.
2. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, *ret*, by DNA rearrangement. *Cell* 1985;42:581-8.
3. Integrated genomic characterization of papillary thyroid carcinoma. *Cell* 2014;159:676-90.
4. Drosten M, Putzer BM. Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. *Nat Clin Pract Oncol* 2006;3:564-74.

5. Schuchardt A, D'Agati V, Larsson-Blomberg L, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. *Nature* 1994;367:380-3.
6. Tsuzuki T, Takahashi M, Asai N, et al. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. *Oncogene* 1995;10:191-8.
7. Ederly P, Lyonnet S, Mulligan LM, et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. *Nature* 1994;367:378-80.
8. Chatterjee R, Ramos E, Hoffman M, et al. Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations. *Hum Genet* 2012;131:1725-38.
9. Wang X. Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET. *Biochim Biophys Acta* 2013;1834:2205-12.
10. Worby CA, Vega QC, Zhao Y, et al. Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. *J Biol Chem* 1996;271:23619-22.
11. Qian Y, Chai S, Liang Z, et al. KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. *Mol Cancer* 2014;13:176.
12. Trupp M, Scott R, Whittemore SR, et al. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. *J Biol Chem* 1999;274:20885-94.
13. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat Med* 2012;18:375-7.
14. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat Med* 2012;18:382-4.
15. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. *Genome Res* 2012;22:436-45.
16. Drilon A, Rogers E, Zhai D, et al. 506P-TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers. *Ann Oncol* 2019;30. doi:10.1093/annonc/mdz244.
17. Das TK, Cagan RL. KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub. *Cell Rep* 2017;20:2368-83.
18. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993;363:458-60.
19. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. *JAMA* 1996;276:1575-9.
20. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med* 2012;18:378-81.
21. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *J Clin Oncol* 2012;30:4352-9.
22. Gautschi O, Milia J, Filleron T, et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. *J Clin Oncol* 2017;35:1403-10.
23. Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Small Cell Lung Cancer: NCCN2017 March 16, 2017.
24. Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. *Nat Rev Clin Oncol* 2018;15:150.
25. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov* 2013;3:630-8.
26. Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. *Lancet Oncol* 2016;17:1653-60.
27. Yoh K, Seto T, Satouchi M, et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. *Lancet Respir Med* 2017;5:42-50.
28. Yoh K, Seto T, Satouchi M, et al. 1487PLURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer. *Ann Oncol* 2018;29:vii493-547.
29. Hida T, Velcheti V, Reckamp KL, et al. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. *Lung Cancer* 2019;138:124-30.
30. Lee SH, Lee JK, Ahn MJ, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. *Ann Oncol* 2017;28:292-7.
31. Horiike A, Takeuchi K, Uenami T, et al. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. *Lung Cancer* 2016;93:43-6.
32. Nokihara H, Nishio M, Yamamoto N, et al. Phase 1 Study

- of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. *Clin Lung Cancer* 2019;20:e317-28.
33. Drilon A, Fu S, Patel MR, et al. A Phase I/II Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. *Cancer Discov* 2019;9:384-95.
 34. Ribeiro M, Alessi JVM, Oliveira LJC, et al. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series. *Lung Cancer* 2020;139:9-12.
 35. Lin JJ, Kennedy E, Sequist LV, et al. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. *J Thorac Oncol* 2016;11:2027-32.
 36. Platt A, Morten J, Ji Q, et al. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. *BMC Cancer* 2015;15:171.
 37. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2018;378:113-25.
 38. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2017;377:829-38.
 39. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21:261-70.
 40. Hayman SR, Leung N, Grande JP, et al. VEGF inhibition, hypertension, and renal toxicity. *Curr Oncol Rep* 2012;14:285-94.
 41. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. *Support Care Cancer* 2011;19:1079-95.
 42. Ferrara R, Auger N, Auclin E, et al. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. *J Thorac Oncol* 2018;13:27-45.
 43. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Mol Cancer Ther* 2011;10:2298-308.
 44. Plenker D, Riedel M, Bragelmann J, et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. *Sci Transl Med* 2017;9. doi: 10.1126/scitranslmed.aah6144.
 45. Huang Q, Schneeberger VE, Luetteke N, et al. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. *Mol Cancer Ther* 2016;15:2521-9.
 46. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. *Oncogene* 2004;23:6056-63.
 47. Dagogo-Jack I, Stevens SE, Lin JJ, et al. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. *J Thorac Oncol* 2018;13:e226-7.
 48. Nakaoku T, Kohno T, Araki M, et al. A secondary RET mutation in the activation loop conferring resistance to vandetanib. *Nat Commun* 2018;9:625.
 49. Nelson-Taylor SK, Le AT, Yoo M, et al. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. *Mol Cancer Ther* 2017;16:1623-33.
 50. Rich TA, Reckamp KL, Chae YK, et al. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. *Clin Cancer Res* 2019;25:5832-42.
 51. Subbiah V, Berry J, Roxas M, et al. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET rearranged non-small cell lung cancer with brain metastases. *Lung Cancer* 2015;89:76-9.
 52. Subbiah V, Cascone T, Hess KR, et al. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. *J Clin Oncol* 2018;36:9035-.
 53. Drilon A, Bergagnini I, Delasos L, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. *Ann Oncol* 2016;27:1286-91.
 54. Takeda M, Sakai K, Nishio K, et al. Successful long-term treatment of non-small cell lung cancer positive for RET rearrangement with pemetrexed. *Onco Targets Ther* 2019;12:5355-8.
 55. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019;30:1321-8.
 56. Offin M, Guo R, Wu SL, et al. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. *JCO Precis Oncol* 2019;1-8. doi: 10.1200/PO.18.00386.
 57. Guisier F, Dubos-Arvis C, Vinas F, et al. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET

- Mutations or RET Translocation: GFPC 01-2018. *J Thorac Oncol* 2020;15:628-36.
58. Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. *Ann Oncol* 2018;29:1869-76.
 59. Velcheti V, Bauer T, Subbiah V, et al. OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases. *J Thorac Oncol* 2017;12:S1778.
 60. Drilon A, Oxnard G, Wirth L, et al. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. *J Thorac Oncol* 2019;14:S6-7.
 61. Subbiah V, Gainor JF, Rahal R, et al. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. *Cancer Discov* 2018;8:836-49.
 62. Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). *J Clin Oncol* 2019;37:9008.
 63. Drilon A, Lin JJ, Filleron T, et al. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. *J Thorac Oncol* 2018;13:1595-601.
 64. Guo R, Schreyer M, Chang JC, et al. Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases. *JCO Precis Oncol* 2019;3. doi: 10.1200/PO.19.00021.
 65. Solomon BJ, Tan L, Lin JJ, et al. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-driven malignancies. *J Thorac Oncol* 2020;15:541-9.

Cite this article as: Choudhury NJ, Drilon A. Decade in review: a new era for RET-rearranged lung cancers. *Transl Lung Cancer Res* 2020. doi: 10.21037/tlcr-20-346